The Legend Holdings-backed molecular diagnostics tool provider will use the $91.6m to help bring its products to market.
Coyote Bioscience, a China-based molecular diagnostics technology provider backed by conglomerate Legend Holdings, has raised almost RMB600m ($91.6m) in series D funding, DealStreetAsia has reported.
The round was led by GL Ventures, the venture capital arm of hedge fund manager Hillhouse Capital, and included Grand Mount Capital, Kinghall Ventures and FreesFund.
Founded in 2009, Coyote initially provided temperature controllers but later pivoted towards providing point-of-care testing.
The company develops tools for portable point-of-care molecular diagnostics as well as for pathogen…
